Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Vorolanib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 65,000Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EyePoint Initiates DURAVYU Ph 3 Trials for Diabetic Macular Edema
    EyePoint Initiates DURAVYU Ph 3 Trials for Diabetic Macular Edema

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247217/0/en/EyePoint-Announces-First-Patients-Dosed-in-Both-Global-Phase-3-Clinical-Trials-of-DURAVYU-for-the-Treatment-of-Diabetic-Macular-Edema.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Eyepoint Unveils Corporate Update And Key 2026 Milestones
    Eyepoint Unveils Corporate Update And Key 2026 Milestones

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214377/0/en/EyePoint-Reports-Corporate-Update-and-Anticipated-Pivotal-Milestones-for-2026.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    EyePoint Starts Ph3 DURAVYU Program in Diabetic Macular Edema
    EyePoint Starts Ph3 DURAVYU Program in Diabetic Macular Edema

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3166631/0/en/EyePoint-Announces-Pivotal-Phase-3-Program-Initiation-for-DURAVYU-in-Diabetic-Macular-Edema.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share
    EyePoint Reports Positive Results for Duravyu in Macular Edema
    EyePoint Reports Positive Results for Duravyu in Macular Edema

    05 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/05/3021051/0/en/EyePoint-Announces-Positive-Six-Month-Results-for-the-Phase-2-VERONA-Clinical-Trial-of-DURAVYU-for-Diabetic-Macular-Edema-Meeting-Primary-and-Secondary-Endpoints.html

    GLOBENEWSWIRE
    05 Feb 2025
    Share Share
    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress
    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress

    26 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/26/2904464/0/en/EyePoint-Pharmaceuticals-to-Highlight-DURAVYU-vorolanib-intravitreal-insert-Clinical-and-Regulatory-Progress-and-Pipeline-Innovation-at-R-D-Day-2024.html

    GLOBENEWSWIRE
    26 Jun 2024
    Share Share
    EyePoint Shows Updated Positive Interim Data from Phase 1 Trial of EYP-1901
    EyePoint Shows Updated Positive Interim Data from Phase 1 Trial of EYP-1901

    12 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/eyepoint-pharmaceuticals-announces-updated-positive-interim-safety-and-efficacy-data-from-ongoing-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd-301481159.html

    PRNEWSWIRE
    12 Feb 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.